Login
Companies $JSPR
$12.41 +$0.64 (5.44%) After hours
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc.

jaspertx.com

What Do They Do?

Develops briquilimab, an antibody therapy for mast cell-driven diseases, for patients with chronic urticaria and asthma.

Who Are Their Customers?

The company is developing therapies for patients with chronic spontaneous and inducible urticaria and asthma.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
  • Sep 23, 2026 The chief financial officer resigned. The chief financial officer resigned, and the chief executive officer became interim principal financial officer.
  • Aug 14, 2026 Jasper completed its acquisition of Kira Pharmaceuticals. The all-stock acquisition closed in July 2026, expanding the company’s pipeline to include complement therapies.

A narrower therapeutic focus The older report described development of therapies for mast and stem cell diseases, including transplant conditioning, blood disorders, and engineered stem cells. The latest report says stem-cell programs have been discontinued and the company is focused exclusively on mast cell-driven diseases.

Who Do They Compete With?

Competes with Celldex Therapeutics, Blueprint Medicines, Novartis, Sanofi Aventis, and Evommune

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support